TGFB1 and myocardial ischemia: In line with this hypothesis, studies using rat and feline models of cardiac ischemia reperfusion showed that treatment with exogenous TGF-β1 in the acute phase (ie, during ischemia and before reperfusion) reduces myocardial injury within the first 24 hours of reperfusion.19